Gaucher disease type 1
Metabolic · 2012–2015
4decisions
3medicines
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| eliglustat Treatment of Gaucher disease type 1 (GD1) in adult patients aged ≥18 years with at least one GD1-related disease manifestation (skeletal disease,… | Jul 2015 | Not recommended | none received |
| taliglucerase alfa Long-term enzyme replacement therapy for patients with a confirmed diagnosis of Gaucher disease. The submission sought listing for enzyme replacement therapy… | Mar 2012 | Not recommended | unclear |
| velaglucerase alfa treatment of type 1 Gaucher disease in a patient who meets certain criteria, as per the Life Saving Drugs Program (LSDP) | Mar 2012 | Deferred | unclear |
| velaglucerase alfa Long-term enzyme replacement therapy for paediatric and adult patients with Type 1 Gaucher disease associated with at least one of the following clinical… | Mar 2012 | Deferred | unclear |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.